SPQS SPORTS QUEST, INC. (OTC: SPQS) – Change in Corporate Vision
Bottling Equipment Sold Hyper Growth Possibility Identified
WEST PALM BEACH, FLORIDA,– September 21, 2022 (OTC MARKETS) – Sports Quest (OTC Markets:
SPQS), a Delaware corporation (the “Company” or “SPQS”), www.sports-quest.com announces a
material event the sale of its water bottling equipment, and change of direction for the Company.
Our Company motto is: The company is also engaged in certain product lines; including other "unicorn"
types of products and in non-aligned industry spaces encompassing new or emerging technologies with
hyper-growth type opportunities. We believe that this is our destiny.
Out with the Old:
This machinery was purchased in an auction house with a retail value close to $1 million dollars. Due to
the ex-management, certain miss allocation of common shares to friends and relatives, and a
subsequent lawsuit SPQS launched in a Federal court in NY to recover over 4,5 Billion shares; our
priorities and focus changed. While we still own the brand “Clear Voda” we sold our equipment to our
co packaging supplier AZ Bottled Water (OTC HIRU) although for common stock we are happy with the
outcome. We are in talks with another issuer to purchase our Clear Soda brand name. Ms. Kathryn
Gavin will be resigning from her position with Sports Quest as its advisor. Ms. Gavin stated…” It is time
for me to focus on HIRU Arizona operations with our recently announced expansion plans. SPQS just lost
its interest in the beverage industry as they are in a mindset of a name change and symbol change with
a unicorn type business model. We part company on good terms and wish the new management all the
best”.
In with the new:
SPQS management is in discussions with Zepter International. https://www.zepter.com/ for a certain
cooperating and marketing agreement. See https://starlite.racing/ and Zepter devices. The space can
better be described as a Meta Verse. https://www.forbes.com/sites/deborahlovich/20...443edb2704 Many changes will be available in the
public domain on SPQS. We are providing this filing to our followers to thwart any false speculations
which may be circulating in the social media platforms. OTC space is a new venture for the Zepter
Group and they are proceeding cautiously. We are attempting as a company to be as transparent as we
can with all of our investors, followers and incoming potential partners.
We have already announced our intention to do a name change and a symbol change. This is well
underway.
With the sale of water equipment and other business ventures we as a company will move forward with
the new team in this new direction with the outlook of filing multiple SEC filings and becoming a SEC
reporting issuer in 2023
Our new business description will be posted on OTC shortly:
https://www.otcmarkets.com/stock/SPQS/profile
The company is in the process of a name change and symbol change having just liquidated its beverage
operations and equipment. Flush with cash we are looking into several up and coming industry spaces.
We are also engaged in R&D and experimental type energy product lines. The company is developing
certain "unicorn" types of products and in non-aligned industry spaces encompassing new or emerging
technologies with hyper-growth type opportunities.
OUT:
Ray Carolin
Kate Gavin
IN:
Sanja Pekovic
Bio:
Sanja Pekovic, PhD, Principal Scientist
Cellular and Molecular Basis of Neuroinflammation: Potential Targets for Translational Medicine and
Therapy, Project leader:
The research focus of this project is to highlight some cellular and molecular mechanisms which
underlie neuroinflammation, to identify potential target molecules and signaling pathways. Our aim is to
find adequate therapeutic approaches for sanitation of neuroinflammation and promotion of
regeneration after the central nervous system (CNS) damage. The efficacy of several therapeutic
approaches (purine nucleoside analogues: Ribavirin and Tiazofurin, hyperbaric oxygenation, B vitamins -
B1, B2, B3, B6, B12) in suppression of detrimental and enhancement of beneficial inflammatory
mechanisms is tested. Considering the pivotal role of extracellular purine nucleotides and nucleosides in
the control of neurodegenerative processes and inflammatory responses a particular focus is put on
regulation of their metabolism and the role of ectonucleotidases. In different animal models (brain
injury, multiple sclerosis: experimental autoimmune encephalomyelitis, ischemia) behavioral, cellular
and molecular approaches (enzymatic assays, microdialysis combined with HPLC and bioluminescent
detection, RT-PCR, immunoblot and immunohistochemistry, ELISA, confocal microscopy and whole cell
patch clamp) are used. Besides in vivo, neuroinflammatory processes are also studied in vitro in primary
astrocytic and microglial cell culture, and glial cell lines. The main goal of the project is to identify,
characterize and standardize potential early and sensitive biomarkers of neuroinflammation and
neurodegeneration that can be used in clinical and laboratory practice for diagnosis and prognosis of
patient outcome after damage to the CNS and for assessing the effectiveness of applied therapies. The
project consists of 2 subprojects: 1) The role of purinergic signalling in acute and chronic
neuroinflammation. 2) Investigation of potential therapeutic approaches for sanitation of
neuroinflammation and promotion of regeneration after damage to the central nervous system
(principal investigator, Sanja Pekovic, PhD).
More details will follow on a timely basis.
Disclaimer Regarding Forward Looking Statements
Certain statements that we make may constitute “forward-looking statements” under the Private
Securities Litigation Reform Act of 1995. Forward-looking statements include information concerning
future strategic objectives, business prospects, anticipated savings, financial results (including expenses,
earnings, liquidity, cash flow and capital expenditures), industry or market conditions, demand for and
pricing of our products, acquisitions and divestitures, anticipated results of litigation and regulatory
developments or general economic conditions. In addition, words such as “believes,” “expects,”
“anticipates,” “intends,” “plans,” “estimates,” “projects,” “forecasts,” and future or conditional verbs
such as “will,” “may,” “could,” “should,” and “would,” as well as any other statement that necessarily
depends on future events, are intended to identify forward-looking statements. Forward-looking
statements are not guarantees, and they involve risks, uncertainties and assumptions. Although we
make such statements based on assumptions that we believe to be reasonable, there can be no
assurance that actual results will not differ materially from those expressed in the forward-looking
statements. We caution investors not to rely unduly on any forward-looking statements.
CONTACT:
SPQS Management Contact info:
Twitter @SpqsOtc
Phone: +1 561 631 9221
Email: ir@sports-quest.co
Web:https://sports-quest.co
https://www.otcmarkets.com/otcapi/company/fin...03/content
Bottling Equipment Sold Hyper Growth Possibility Identified
WEST PALM BEACH, FLORIDA,– September 21, 2022 (OTC MARKETS) – Sports Quest (OTC Markets:
SPQS), a Delaware corporation (the “Company” or “SPQS”), www.sports-quest.com announces a
material event the sale of its water bottling equipment, and change of direction for the Company.
Our Company motto is: The company is also engaged in certain product lines; including other "unicorn"
types of products and in non-aligned industry spaces encompassing new or emerging technologies with
hyper-growth type opportunities. We believe that this is our destiny.
Out with the Old:
This machinery was purchased in an auction house with a retail value close to $1 million dollars. Due to
the ex-management, certain miss allocation of common shares to friends and relatives, and a
subsequent lawsuit SPQS launched in a Federal court in NY to recover over 4,5 Billion shares; our
priorities and focus changed. While we still own the brand “Clear Voda” we sold our equipment to our
co packaging supplier AZ Bottled Water (OTC HIRU) although for common stock we are happy with the
outcome. We are in talks with another issuer to purchase our Clear Soda brand name. Ms. Kathryn
Gavin will be resigning from her position with Sports Quest as its advisor. Ms. Gavin stated…” It is time
for me to focus on HIRU Arizona operations with our recently announced expansion plans. SPQS just lost
its interest in the beverage industry as they are in a mindset of a name change and symbol change with
a unicorn type business model. We part company on good terms and wish the new management all the
best”.
In with the new:
SPQS management is in discussions with Zepter International. https://www.zepter.com/ for a certain
cooperating and marketing agreement. See https://starlite.racing/ and Zepter devices. The space can
better be described as a Meta Verse. https://www.forbes.com/sites/deborahlovich/20...443edb2704 Many changes will be available in the
public domain on SPQS. We are providing this filing to our followers to thwart any false speculations
which may be circulating in the social media platforms. OTC space is a new venture for the Zepter
Group and they are proceeding cautiously. We are attempting as a company to be as transparent as we
can with all of our investors, followers and incoming potential partners.
We have already announced our intention to do a name change and a symbol change. This is well
underway.
With the sale of water equipment and other business ventures we as a company will move forward with
the new team in this new direction with the outlook of filing multiple SEC filings and becoming a SEC
reporting issuer in 2023
Our new business description will be posted on OTC shortly:
https://www.otcmarkets.com/stock/SPQS/profile
The company is in the process of a name change and symbol change having just liquidated its beverage
operations and equipment. Flush with cash we are looking into several up and coming industry spaces.
We are also engaged in R&D and experimental type energy product lines. The company is developing
certain "unicorn" types of products and in non-aligned industry spaces encompassing new or emerging
technologies with hyper-growth type opportunities.
OUT:
Ray Carolin
Kate Gavin
IN:
Sanja Pekovic
Bio:
Sanja Pekovic, PhD, Principal Scientist
Cellular and Molecular Basis of Neuroinflammation: Potential Targets for Translational Medicine and
Therapy, Project leader:
The research focus of this project is to highlight some cellular and molecular mechanisms which
underlie neuroinflammation, to identify potential target molecules and signaling pathways. Our aim is to
find adequate therapeutic approaches for sanitation of neuroinflammation and promotion of
regeneration after the central nervous system (CNS) damage. The efficacy of several therapeutic
approaches (purine nucleoside analogues: Ribavirin and Tiazofurin, hyperbaric oxygenation, B vitamins -
B1, B2, B3, B6, B12) in suppression of detrimental and enhancement of beneficial inflammatory
mechanisms is tested. Considering the pivotal role of extracellular purine nucleotides and nucleosides in
the control of neurodegenerative processes and inflammatory responses a particular focus is put on
regulation of their metabolism and the role of ectonucleotidases. In different animal models (brain
injury, multiple sclerosis: experimental autoimmune encephalomyelitis, ischemia) behavioral, cellular
and molecular approaches (enzymatic assays, microdialysis combined with HPLC and bioluminescent
detection, RT-PCR, immunoblot and immunohistochemistry, ELISA, confocal microscopy and whole cell
patch clamp) are used. Besides in vivo, neuroinflammatory processes are also studied in vitro in primary
astrocytic and microglial cell culture, and glial cell lines. The main goal of the project is to identify,
characterize and standardize potential early and sensitive biomarkers of neuroinflammation and
neurodegeneration that can be used in clinical and laboratory practice for diagnosis and prognosis of
patient outcome after damage to the CNS and for assessing the effectiveness of applied therapies. The
project consists of 2 subprojects: 1) The role of purinergic signalling in acute and chronic
neuroinflammation. 2) Investigation of potential therapeutic approaches for sanitation of
neuroinflammation and promotion of regeneration after damage to the central nervous system
(principal investigator, Sanja Pekovic, PhD).
More details will follow on a timely basis.
Disclaimer Regarding Forward Looking Statements
Certain statements that we make may constitute “forward-looking statements” under the Private
Securities Litigation Reform Act of 1995. Forward-looking statements include information concerning
future strategic objectives, business prospects, anticipated savings, financial results (including expenses,
earnings, liquidity, cash flow and capital expenditures), industry or market conditions, demand for and
pricing of our products, acquisitions and divestitures, anticipated results of litigation and regulatory
developments or general economic conditions. In addition, words such as “believes,” “expects,”
“anticipates,” “intends,” “plans,” “estimates,” “projects,” “forecasts,” and future or conditional verbs
such as “will,” “may,” “could,” “should,” and “would,” as well as any other statement that necessarily
depends on future events, are intended to identify forward-looking statements. Forward-looking
statements are not guarantees, and they involve risks, uncertainties and assumptions. Although we
make such statements based on assumptions that we believe to be reasonable, there can be no
assurance that actual results will not differ materially from those expressed in the forward-looking
statements. We caution investors not to rely unduly on any forward-looking statements.
CONTACT:
SPQS Management Contact info:
Twitter @SpqsOtc
Phone: +1 561 631 9221
Email: ir@sports-quest.co
Web:https://sports-quest.co
https://www.otcmarkets.com/otcapi/company/fin...03/content
